Zydus Lifesciences Limited and Formycon AG have announced that the US Food and Drug Administration (USFDA) has accepted the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda® (pembrolizumab), for review.
According to the companies, this is the first publicly announced acceptance by the USFDA of an application for a proposed Keytruda biosimilar, to the best of their knowledge. The application was submitted during the third quarter of 2026, marking an important regulatory milestone in the development of a potential biosimilar to one of the world's best-selling biologic medicines.
The FDA's review timeline under the Biosimilar User Fee Amendments (BsUFA) targets completion within 12 months of submission. Based on the companies' stated timeline, a regulatory decision could be expected in the third quarter of 2027. The regulatory dossier for FYB206 has also been submitted to Health Canada.
FYB206 Developed Without a Comparative Phase III Efficacy Trial
One notable aspect of the FYB206 development programme is that it proceeded without a comparative Phase III efficacy trial. Formycon stated that this development pathway was agreed upon with the USFDA in February 2025.
According to the company, this approach helped accelerate development and substantially reduce investment requirements while maintaining the scientific standards necessary for biosimilar approval.
Acceptance of the BLA for review does not mean that FYB206 has been approved for marketing. The proposed biosimilar must still undergo regulatory evaluation, and commercialization will depend on the relevant approvals and resolution of any applicable intellectual property issues.
Zydus to Commercialize FYB206 in the US and Canada
Under an exclusive licensing and supply agreement signed in December 2025, Zydus holds exclusive commercialization rights for FYB206 in the United States and Canada.
Formycon is responsible for completing development, preparing and filing regulatory dossiers, and supplying the product. Zydus will lead commercialization in the two markets, subject to regulatory approval and applicable intellectual property considerations. Formycon retains global rights to FYB206 and will participate in the gross profits generated by its commercialization partners.
The FDA's acceptance of the application also represents a contractual regulatory milestone that entitles Formycon to a milestone payment from Zydus.
Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited, said the milestone represents progress towards potentially expanding access to affordable pembrolizumab therapy in the US and Canada. He highlighted the companies' complementary capabilities in biologics development and oncology commercialization.
Dr. Stefan Glombitza, CEO of Formycon AG, also described the acceptance as a significant step for the programme, emphasizing the development pathway agreed with the FDA and the partnership with Zydus.
What Is Pembrolizumab and Why Is It Important?
Pembrolizumab is an immune checkpoint inhibitor that binds to and blocks the programmed cell death protein 1 (PD-1) receptor. By interfering with this immune checkpoint, the medicine can help the immune system recognize and attack cancer cells.
Marketed as Keytruda®, pembrolizumab is used in the treatment of multiple cancer types and has become a major medicine in oncology.
According to the companies' announcement, worldwide sales of Keytruda®, including the subcutaneous formulation Keytruda Qlex™, reached USD 31.7 billion in 2025. Combined sales of the two formulations totalled US$16.40 billion in the first half of 2026, reinforcing the commercial significance of the product.
Potential Significance for the Biosimilars Market
The development of FYB206 highlights the growing commercial interest in biosimilars targeting high-value biologic medicines used in cancer care.
If approved, FYB206 could provide an additional treatment option in the US and Canadian markets. Biosimilar competition may contribute to greater treatment accessibility and affordability, although actual pricing, market uptake and patient access will depend on regulatory outcomes, commercial strategies and reimbursement arrangements.
For Zydus, the programme represents an opportunity to strengthen its oncology biosimilars portfolio in North America. For Formycon, FDA acceptance marks a significant step towards potential commercialization of its proposed pembrolizumab biosimilar.
The next major milestone will be the outcome of the FDA's review, potentially in the third quarter of 2027. Until approval is granted, FYB206 remains an investigational proposed biosimilar and is not yet authorized for marketing on the basis of this announcement.
